Menu
 

You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating indiv idual securities.

If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.

OK Cancel

Recent Quotes

No Recent Quote currently available

My Portfolio

My Portfolio Tracker

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today.

Zacks #1 Stocks on the Move 03/22/2017

Company Name Symbol %Change
Performant F PFMT
10.71%
Applied Opto AAOI
9.12%
Sunshine Hea SSH
8.78%
Arotech Corp ARTX
6.90%
Gol Linhas A GOL
4.25%

Tale of the Tape

New Strong Sell Stocks for March 22nd

Posted Wed Mar 22, 11:17 am ET

by Zacks Equity Research

New Strong Sell Stocks for March 22nd

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:

Allied Motion Technologies Inc. AMOT is engaged in the business of designing and selling advanced systems and motion control products. The Zacks Consensus Estimate for its current year earnings has been revised 7.6% downward over the last 30 days.

American Railcar Industries, Inc. ARII is a leading North American manufacturer of covered hopper and tank railcars. The Zacks Consensus Estimate for its current year earnings has been revised 10.5% downward over the last 30 days.

B&G Foods, Inc. BGS sells and distributes a diversified portfolio of high-quality, shelf-stable foods across the U.S. and Canada. The Zacks Consensus Estimate for its current year earnings has been revised 9.6% downward over the last 30 days.

Conifer Holdings, Inc. CNFR is an insurance holding company. The Zacks Consensus Estimate for its current year earnings has been revised 25% downward over the last 30 days.

Endeavour Silver Corp. EXK is a mid-cap silver mining company focused on acquisition and exploration in mining properties in Chile and Mexico. The Zacks Consensus Estimate for its current year earnings has been revised 45.9% downward over the last 30 days.

View the entire Zacks Rank #5 List.

Falling Earnings Estimates Signal Weakness Ahead for Impax Laboratories (IPXL)

Posted Wed Mar 22, 09:00 am ET

by Zacks Equity Research

Similar to wise buying decisions, exiting certain underperformers at the right time helps maximize portfolio returns. Selling off losers can be difficult, but if both the share price and estimates are falling, it could be time to get rid of the security before more losses hit your portfolio.

One such stock that you may want to consider dropping is Impax Laboratories, Inc. IPXL, which has witnessed a significant price decline in the past four weeks, and it has seen negative earnings estimate revisions for the current quarter and the current year. A Zacks Rank #5 (Strong Sell) further confirms weakness in IPXL.

A key reason for this move has been the negative trend in earnings estimate revisions. For the full year, we have seen six estimates moving down in the past 30 days, compared with no upward revisions. This trend has caused the consensus estimate to trend lower, going from $1.37 a share a month ago to its current level of 76 cents.

Also, for the current quarter, Impax has seen two downward estimate revisions versus no revisions in the opposite direction, dragging the consensus estimate down to 14 cents a share from 31 cents over the past 30 days.  

The stock also has seen some pretty dismal trading lately, as the share price has dropped 37.3% in the past month.

So it may not be a good decision to keep this stock in your portfolio anymore, at least if you don’t have a long time horizon to wait.

If you are still interested in the Medical sector, you may instead consider a better-ranked stock - Sunshine Heart, Inc. SSH. The stock currently holds a Zacks Rank #1 (Strong Buy) and may be a better selection at this time. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

5 Trades Could Profit "Big-League" from Trump Policies

If the stocks above spark your interest, wait until you look into companies primed to make substantial gains from Washington's changing course.

Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals, tariffs, lower taxes, higher interest rates, and spending surges in defense and infrastructure. See these buy recommendations now >>

Looking for Value? Why It Might Be Time to Try Denso Corp. (DNZOY)

Posted Wed Mar 22, 08:55 am ET

by Zacks Equity Research

Value investing is always a very popular strategy, and for good reason. After all, who doesn’t want to find stocks that have low PEs, solid outlooks, and decent dividends?

Fortunately for investors looking for this combination, we have identified a strong candidate which may be an impressive value; Denso Corporation DNZOY.

Denso Corp. in Focus

DNZOY may be an interesting play thanks to its forward PE of 16.75, its P/S ratio of 0.88, and its decent dividend yield of 1.85%. These factors suggest that Denso Corp. is a pretty good value pick, as investors have to pay a relatively low level for each dollar of earnings, and that DNZOY has decent revenue metrics to back up its earnings.

Denso Corp. PE Ratio (TTM)

But before you think that Denso Corp. is just a pure value play, it is important to note that it has been seeing solid activity on the earnings estimate front as well. For current year earnings, the consensus has gone up by 9.5% in the past 30 days, thanks to one upward revision in the past one month compared to none lower.

This estimate strength is actually enough to push DNZOY to a Zacks Rank #2 (Buy), suggesting it is poised to outperform. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

So really, Denso Corp. is looking great from a number of angles thanks to its PE below 20, a P/S ratio below one, and a strong Zacks Rank, meaning that this company could be a great choice for value investors at this time.

5 Trades Could Profit "Big-League" from Trump Policies

If the stocks above spark your interest, wait until you look into companies primed to make substantial gains from Washington's changing course.

Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals, tariffs, lower taxes, higher interest rates, and spending surges in defense and infrastructure. See these buy recommendations now >>

Looking for a Top Momentum Stock? 3 Reasons Why Everi Holdings (EVRI) is a Great Choice

Posted Wed Mar 22, 08:51 am ET

by Zacks Equity Research

Many investors like to look for momentum in stocks, but this can be very tough to define. There is great debate regarding which metrics are the best to focus on in this regard, and which are not really quality indicators of future performance. Fortunately, with our new style score system we have identified the key statistics to pay close attention to and thus which stocks might be the best for momentum investors in the near term.

This method discovered several great candidates for momentum-oriented investors, but today let’s focus in on Everi Holdings Inc. EVRI as this stock is looking especially impressive right now. And while there are numerous ways in which this company could be a great choice, we have highlighted three of the most vital reasons for EVRI’s status as a solid momentum stock below:

Short Term Price Change for Everi Holdings

A great place to look for finding momentum stocks is by inspecting short term price activity. This can help to reflect the current interest in a stock and if buyers or sellers have the upper hand right now. It is especially useful to compare it to the industry as this can help investors pinpoint the top companies in a particular area.

With a one week price change of 27.7% compared to an industry average of 0.8%, EVRI is certainly well-positioned in this regard. The stock is also looking quite well from a longer time frame too, as the four week price change compares favorably with the industry at large as well.

Everi Holdings Inc. Price

Longer Term Price Change for Everi Holdings

While any stock can see a spike in price, it takes a real winner to consistently outperform the market. That is why looking at longer term price metrics—such as performance over the past three months or year-- and comparing these to an industry at large can be very useful.

And in the case of EVRI, the results are quite impressive. The company has beaten out the industry at large over the past 12 weeks by a margin of 74.5% to 0% while it has also outperformed when looking at the past year, putting up a gain of 82%. Clearly, EVRI is riding a bit of a hot streak and is worth a closer look by investors.  

EVRI Earnings Estimate Revisions Moving in the Right Direction

While the great momentum factors outlined in the preceding paragraphs might be enough for some investors, we should also take into account broad earnings estimate revision trends. A nice path here can really help to show us a promising stock, and we have actually been seeing that with EVRI as of late too.

Over the past month, one earnings estimate has gone higher compared to none lower for the full year. These revisions have helped to boost the consensus estimate as a month ago EVRI was expected to post a loss of 61 cents per share for the full year, though today it looks to post a loss of 47 cents for the full year, representing a solid increase which is something that should definitely be welcomed news to would-be investors.

Bottom Line

Given these factors, investors shouldn’t be surprised to note that we have EVRI as a security with a Zacks Rank #2 (Buy) and a Momentum Score of ‘A’. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

So if you are looking for a fresh pick that has potential to move in the right direction, definitely keep EVRI on your short list as this looks be a stock that is very well-positioned to soar in the near term.

5 Trades Could Profit "Big-League" from Trump Policies

If the stocks above spark your interest, wait until you look into companies primed to make substantial gains from Washington's changing course.

Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals, tariffs, lower taxes, higher interest rates, and spending surges in defense and infrastructure. See these buy recommendations now >>

What Makes Trevena (TRVN) a Strong Sell?

Posted Wed Mar 22, 08:50 am ET

by Zacks Equity Research

Similar to wise buying decisions, exiting certain underperformers at the right time helps maximize portfolio returns. Selling off losers can be difficult, but if both the share price and estimates are falling, it could be time to get rid of the security before more losses hit your portfolio.

One such stock that you may want to consider dropping is Trevena, Inc. TRVN, which has witnessed a significant price decline in the past four weeks, and it has seen negative earnings estimate revisions for the current quarter and the current year. A Zacks Rank #4 (Sell) further confirms weakness in TRVN.

A key reason for this move has been the negative trend in earnings estimate revisions. For the full year, we have seen 5 estimates moving down in the past 30 days, compared with no upward revisions. This trend has caused the consensus estimate to trend lower, going from a loss of $1.52 a share a month ago to its current level of a loss of $1.79.

Also, for the current quarter, TRVN has seen 3 downward estimate revision versus no revision in the opposite direction, dragging the consensus estimate down to a loss of 50 cents a share from a loss of 46 cents over the past 30 days.    

The stock also has seen some pretty dismal trading lately, as the share price has dropped 18% in the past month.

Trevena, Inc. Price and Consensus

So it may not be a good decision to keep this stock in your portfolio anymore, at least if you don’t have a long time horizon to wait.

If you are still interested in the Medical - Biomedical and Genetics industry, you may instead consider a better-ranked stock - Galena Biopharma, Inc. (GALE). The stock currently holds a Zacks Rank #1 (Strong Buy) and may be a better selection at this time. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

5 Trades Could Profit ""Big-League"" from Trump Policies

If the stocks above spark your interest, wait until you look into companies primed to make substantial gains from Washington's changing course.

Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals, tariffs, lower taxes, higher interest rates, and spending surges in defense and infrastructure. See these buy recommendations now >>

Is Nucor (NUE) Stock a Solid Choice Right Now?

Posted Wed Mar 22, 08:47 am ET

by Zacks Equity Research

One stock that might be an intriguing choice for investors right now is Nucor Corporation NUE. This is because this security in the Steel - Producers space is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective.

This is important because, often times, a rising tide will lift all boats in an industry, as there can be broad trends taking place in a segment that are boosting securities across the board. This is arguably taking place in the Steel - Producersspace as it currently has a Zacks Industry Rank of 20 out of more than 250 industries, suggesting it is well-positioned from this perspective, especially when compared to other segments out there.

Meanwhile, Nucoris actually looking pretty good on its own too. The firm has seen solid earnings estimate revision activity over the past month, suggesting analysts are becoming a bit more bullish on the firm’s prospects in both the short and long term.

Nucor Corporation Price and Consensus

In fact, over the past month, while current quarter estimates have risen from 76 cents per share to $1.13 per share, current year estimates have risen from $3.78 per share to $3.82 per share. The company currently carries a Zacks Rank #3 (Hold), which is also a favorable signal.You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

So, if you are looking for a decent pick in a strong industry, consider Nucor. Not only is its industry currently in the top third, but it is seeing solid estimate revisions as of late, suggesting it could be a very interesting choice for investors seeking a name in this great industry segment.

5 Trades Could Profit ""Big-League"" from Trump Policies

If the stocks above spark your interest, wait until you look into companies primed to make substantial gains from Washington's changing course.

Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals, tariffs, lower taxes, higher interest rates, and spending surges in defense and infrastructure. See these buy recommendations now >>

Investors in Aurinia Pharmaceuticals Inc. AUPH need to pay close attention to the stock based on moves in the options market lately. That is because the July 21st, 2017 $2.50 Call had some of the highest implied volatility of all equity options today.

What is Implied Volatility?

Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other. It could also mean there is an event coming up soon that may cause a big rally or a huge sell off. However, implied volatility is only one piece of the puzzle when putting together an options trading strategy.

What do the Analysts Think?

Clearly, options traders are pricing in a big move for Aurinia Pharmaceuticals shares, but what is the fundamental picture for the company? Currently, Aurinia Pharmaceuticals is a Zacks Rank #3 (Hold) in the Medical - Drugs industry that ranks in the Top 35% of our Zacks Industry Rank. Over the last 60 days, one analyst has increased earnings estimates for the current quarter, while no analyst has revised their estimates downward. The net effect has taken our Zacks Consensus Estimate for the current quarter from a loss of 11 cents per share to a loss of 12 cents in that period. 

Given the way analysts feel about Aurinia Pharmaceuticals right now, this huge implied volatility could mean there’s a trade developing. Often times, options traders look for options with high levels of implied volatility to sell premium. This is a strategy many seasoned traders use because it captures decay. At expiration, the hope for these traders is that the underlying stock does not move as much as originally expected.

Looking to Trade Options? 

Each week, our very own Dave Bartosiak gives his top options trades. Check out his recent live analysis and options trade for the LULU earnings report completely free. See it here: Bartosiak: Trading Ulta (ULTA) Earnings with Options or check out the embedded video below for more details:

Why Allianz (AZSEY) Could Be a Top Value Stock Pick

Posted Wed Mar 22, 08:45 am ET

by Zacks Equity Research

Value investing is always a very popular strategy, and for good reason. After all, who doesn’t want to find stocks that have low PEs, solid outlooks, and decent dividends?

Fortunately for investors looking for this combination, we have identified a strong candidate which may be an impressive value; Allianz SE AZSEY.

Allianz in Focus

AZSEY may be an interesting play thanks to its forward PE of 10.67, its P/S ratio of 0.62, and its decent dividend yield of 3.35%. These factors suggest that Allianz is a pretty good value pick, as investors have to pay a relatively low level for each dollar of earnings, and that AZSEY has decent revenue metrics to back up its earnings.

Allianz SE PE Ratio (TTM)

But before you think that Allianz is just a pure value play, it is important to note that it has been seeing solid activity on the earnings estimate front as well. For current year earnings, the consensus has gone up by 2.4% in the past 30 days, thanks to one upward revision in the past one month compared to none lower.

This estimate strength is actually enough to push AZSEY to a Zacks Rank #2 (Buy), suggesting it is poised to outperform. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

So really, Allianz is looking great from a number of angles thanks to its PE below 20, a P/S ratio below one, and a strong Zacks Rank, meaning that this company could be a great choice for value investors at this time.

5 Trades Could Profit "Big-League" from Trump Policies

If the stocks above spark your interest, wait until you look into companies primed to make substantial gains from Washington's changing course.

Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals, tariffs, lower taxes, higher interest rates, and spending surges in defense and infrastructure. See these buy recommendations now >>

Implied Volatility Surging for Activision Blizzard (ATVI) Stock Options

Posted Wed Mar 22, 08:43 am ET

by Zacks Equity Research

Investors in Activision Blizzard, Inc. ATVI need to pay close attention to the stock based on moves in the options market lately. That is because the March 24th, 2017 $43.5 Call had some of the highest implied volatility of all equity options today.

What is Implied Volatility?

Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other. It could also mean there is an event coming up soon that may cause a big rally or a huge sell off. However, implied volatility is only one piece of the puzzle when putting together an options trading strategy.

What do the Analysts Think?

Clearly, options traders are pricing in a big move for Activision Blizzard shares, but what is the fundamental picture for the company? Currently, Activision Blizzard is a Zacks Rank #2 (Buy) in the Toys - Games - Hobbiesindustry that ranks in the Bottom 35% of our Zacks Industry Rank. Over the last 60 days, none of the analysts have increased or decreased their earnings estimates for the current quarter. The net effect has taken our Zacks Consensus Estimate for the current quarter from 19 cents per share to 18 cents in that period. 

Given the way analysts feel about Activision Blizzard right now, this huge implied volatility could mean there’s a trade developing. Often times, options traders look for options with high levels of implied volatility to sell premium. This is a strategy many seasoned traders use because it captures decay. At expiration, the hope for these traders is that the underlying stock does not move as much as originally expected.

Looking to Trade Options? 

Each week, our very own Dave Bartosiak gives his top options trades. Check out his recent live analysis and options trade for the LULU earnings report completely free. See it here: Bartosiak: Trading Ulta (ULTA) Earnings with Options or check out the embedded video below for more details:

Why SP Plus (SP) Stock Might be a Great Pick

Posted Wed Mar 22, 08:43 am ET

by Zacks Equity Research

One stock that might be an intriguing choice for investors right now is SP Plus Corporation SP. This is because this security in the Consumer Services - Miscellaneous space is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective.

This is important because, often times, a rising tide will lift all boats in an industry, as there can be broad trends taking place in a segment that are boosting securities across the board. This is arguably taking place in the Consumer Services - Miscellaneousspace as it currently has a Zacks Industry Rank of 13 out of more than 250 industries, suggesting it is well-positioned from this perspective, especially when compared to other segments out there.

Meanwhile, SP Plus is actually looking pretty good on its own too. The firm has seen solid earnings estimate revision activity over the past month, suggesting analysts are becoming a bit more bullish on the firm’s prospects in both the short and long term.

SP Plus Corporation Price and Consensus

In fact, over the past month, while current quarter estimates have risen from 15 cents per share to 19 cents per share, current year estimates have risen from $1.31 per share to $1.57 per share. This has helped SP to earn a Zacks Rank #1 (Strong Buy), further underscoring the company’s solid position.You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

So, if you are looking for a decent pick in a strong industry, consider SP Plus. Not only is its industry currently in the top third, but it is seeing solid estimate revisions as of late, suggesting it could be a very interesting choice for investors seeking a name in this great industry segment.

5 Trades Could Profit ""Big-League"" from Trump Policies

If the stocks above spark your interest, wait until you look into companies primed to make substantial gains from Washington's changing course.

Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals, tariffs, lower taxes, higher interest rates, and spending surges in defense and infrastructure. See these buy recommendations now >>

Full Archive

The content contained in this weblog feature may have been abstracted from a complete Zacks Equity Research report.

Zacks Research is Reported On:

Zacks Investment Research

is an A+ Rated BBB

Accredited Business.